PDE3A在癌症中的作用
Shengyu Pu1, Qihe Zhang2, Mi Miao2
1Dept. of Nuclear Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China.
ACS omega
|February 23, 2026
概括
二酶3A (PDE3A) 在许多癌症中过度表达,导致瘤生长,转移和耐药性. 抑制PDE3A对新型癌症疗法,特别是对抗性瘤有很大的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 二酶3A (PDE3A) 对于调节周期性核酸水平至关重要,影响血小板激活,心脏功能和血管光滑肌肉细胞增殖.
- 新出现的证据强调了PDE3A在各种恶性瘤的发展和进展中的重要作用.
研究的目的:
- 研究癌症中PDE3A表达的多方面的调节.
- 阐明PDE3A在瘤细胞增殖,转移和化疗耐药性的功能机制.
- 评估PDE3A作为癌症治疗的潜在治疗标.
主要方法:
- 对221篇PubMed索引文章进行了系统审查.
- 分析的重点是PDE3A表达,其调节途径,以及它在癌症特征中的作用.
- 研究了PDE3A抑制策略和治疗潜力.
主要成果:
- 在多种癌症中观察到异常PDE3A过度表达,包括胃肠道瘤,肝细胞癌和乳腺癌.
- PDE3A的表达受到遗传,表观遗传和后翻译机制的调节,通过NF-κB和YAP/TEAD等信号通路影响癌症干细胞特征,转移和耐药性.
- 单独使用或与化疗结合使用的PDE3A抑制剂显示出显著的抗瘤疗效,特别是在耐火性癌症中.
结论:
- 异常PDE3A表达是瘤发生,进展和治疗耐药性的关键驱动因素.
- 通过抑制剂或分子剂向PDE3A为各种癌症提供了一个有希望的治疗策略,特别是那些对常规化疗有耐药性的癌症.
相关概念视频
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Regulation of Angiogenesis and Blood Supply
3.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K


